Osteoarthritis and the Mediterranean DietA Systematic Review

Isabel Morales-Ivorra, Montserrat Romera Baurés, Blanca Román‐Viñas, Lluís Serra‐Majem•View original
HighlightsAccessiblefable voice
Two hundred and forty million people live with osteoarthritis. That's not a statistic to gloss over — it means hundreds of millions of people dealing with joint pain, stiffness, and lost mobility every single day. At the tissue level, osteoarthritis is about cartilage breaking down and chronic inflammation taking hold. The treatments we have mostly manage symptoms. Weight loss and exercise help. But could what you eat actually shift the course of the disease? That's the question a systematic review by Morales-Ivorra and colleagues set out to answer, specifically looking at the Mediterranean diet. When researchers talk about the Mediterranean diet, they mean something concrete: lots of vegetables, fruit, legumes, nuts, and cereals; fish regularly; olive oil as the main fat; and red and processed meat kept to a minimum. To measure how closely someone follows it, researchers use dietary scoring tools. Veronese and colleagues used the Panagiotakos adherence score applied to a food-frequency questionnaire. Dyer and colleagues used a seven-day food diary in a clinical trial. The reason this diet is worth studying for osteoarthritis comes down to inflammation — chronic low-grade inflammation drives osteoarthritis progression, and the Mediterranean diet has been linked to lower inflammatory markers in other contexts. The systematic review found three studies that actually tested this connection. Two were cross-sectional analyses by Veronese and colleagues, drawing on the Osteoarthritis Initiative with samples of over four thousand participants each. The third was a sixteen-week randomized controlled trial by Dyer and colleagues, with ninety-nine people who had clinician-diagnosed osteoarthritis. The Veronese analyses found a clear pattern. People in the highest quartile of Mediterranean diet adherence had a knee osteoarthritis prevalence of twenty-five point two percent, compared to thirty-three point eight percent in the lowest quartile. The odds of having knee osteoarthritis were also lower — an adjusted odds ratio of zero point eighty-three. Higher adherence also tracked with better quality of life scores on the SF-12 physical scale, lower pain and disability on the Western Ontario and McMaster Universities Osteoarthritis Index, and fewer depressive symptoms. The Dyer trial told a more complicated story. Most biomarker and functional outcomes didn't reach statistical significance after sixteen weeks. But one did stand out: interleukin-1 alpha, an inflammatory protein, dropped notably in the Mediterranean diet group, with a p-value of zero point zero one nine. Markers of cartilage degradation fell by roughly eight percent. Hip rotation also improved significantly in the diet group. Here's where honest caution matters. Cross-sectional studies show association, not causation — they can't tell us that the diet caused better outcomes, only that people who eat this way tend to fare better. And sixteen weeks is a short window for a disease that develops over years. The review's authors flag this directly: the brief exposure may explain why many biomarkers in the Dyer trial stayed flat. The signal is real. It's just early. Longer prospective trials are the next step — and in the meantime, there's a reasonable case for thinking carefully about what's on your plate.

Two hundred and forty million people live with osteoarthritis. That's not a statistic to gloss over — it means hundreds of millions of people dealing with joint pain, stiffness, and lost mobility every single day. At the tissue level, osteoarthritis is about cartilage breaking down and chronic inflammation taking hold.

The treatments we have mostly manage symptoms. Weight loss and exercise help. But could what you eat actually shift the course of the disease?

That's the question a systematic review by Morales-Ivorra and colleagues set out to answer, specifically looking at the Mediterranean diet.

When researchers talk about the Mediterranean diet, they mean something concrete: lots of vegetables, fruit, legumes, nuts, and cereals; fish regularly; olive oil as the main fat; and red and processed meat kept to a minimum. To measure how closely someone follows it, researchers use dietary scoring tools. Veronese and colleagues used the Panagiotakos adherence score applied to a food-frequency questionnaire.

Dyer and colleagues used a seven-day food diary in a clinical trial. The reason this diet is worth studying for osteoarthritis comes down to inflammation — chronic low-grade inflammation drives osteoarthritis progression, and the Mediterranean diet has been linked to lower inflammatory markers in other contexts.

The systematic review found three studies that actually tested this connection. Two were cross-sectional analyses by Veronese and colleagues, drawing on the Osteoarthritis Initiative with samples of over four thousand participants each. The third was a sixteen-week randomized controlled trial by Dyer and colleagues, with ninety-nine people who had clinician-diagnosed osteoarthritis.

The Veronese analyses found a clear pattern. People in the highest quartile of Mediterranean diet adherence had a knee osteoarthritis prevalence of twenty-five point two percent, compared to thirty-three point eight percent in the lowest quartile. The odds of having knee osteoarthritis were also lower — an adjusted odds ratio of zero point eighty-three.

Higher adherence also tracked with better quality of life scores on the SF-12 physical scale, lower pain and disability on the Western Ontario and McMaster Universities Osteoarthritis Index, and fewer depressive symptoms.

The Dyer trial told a more complicated story. Most biomarker and functional outcomes didn't reach statistical significance after sixteen weeks. But one did stand out: interleukin-1 alpha, an inflammatory protein, dropped notably in the Mediterranean diet group, with a p-value of zero point zero one nine.

Markers of cartilage degradation fell by roughly eight percent. Hip rotation also improved significantly in the diet group.

Here's where honest caution matters. Cross-sectional studies show association, not causation — they can't tell us that the diet caused better outcomes, only that people who eat this way tend to fare better. And sixteen weeks is a short window for a disease that develops over years.

The review's authors flag this directly: the brief exposure may explain why many biomarkers in the Dyer trial stayed flat.

The signal is real. It's just early. Longer prospective trials are the next step — and in the meantime, there's a reasonable case for thinking carefully about what's on your plate.